-
1.发明公开Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof 有权多成体干细胞，基本物质。确保恢复过程中保护和分化及其方法，使用方法用途，您始发细胞
公开(公告)号：EP1491093A3
公开(公告)日：2005-05-04
申请号：EP04023157.3
申请日：2002-02-14
IPC分类号： A01N63/00
CPC分类号： A61K39/001 , A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/106 , A61K35/12 , A61K48/00 , C12N5/0607 , C12N5/0619 , C12N5/0622 , C12N5/067 , C12N15/873 , C12N2501/11 , C12N2501/113 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/135 , C12N2501/235 , C12N2501/237 , C12N2502/08 , C12N2502/30 , C12N2503/00 , C12N2506/03 , C12N2517/02
摘要： The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.
-
2.发明公开MULTIPOTENT ADULT STEM CELLS, SOURCES THEREOF, METHODS OF OBTAINING AND MAINTAINING SAME, METHODS OF DIFFERENTIATION THEREOF, METHODS OF USE THEREOF AND CELLS DERIVED THEREOF 审中-公开多成体干细胞，基本物质。确保恢复过程中保护和分化及其方法，使用方法用途，您始发细胞
公开(公告)号：EP1367899A2
公开(公告)日：2003-12-10
申请号：EP02718998.4
申请日：2002-02-14
IPC分类号： A01N63/00 , A61K48/00 , C12Q1/02 , C12N5/00 , C12N5/08 , C12N15/00 , C07K1/00 , C07K14/00 , G01N33/48 , G01N33/50
CPC分类号： A61K39/001 , A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/106 , A61K35/12 , A61K48/00 , C12N5/0607 , C12N5/0619 , C12N5/0622 , C12N5/067 , C12N15/873 , C12N2501/11 , C12N2501/113 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/135 , C12N2501/235 , C12N2501/237 , C12N2502/08 , C12N2502/30 , C12N2503/00 , C12N2506/03 , C12N2517/02
摘要： An isolated multipotent adult stem cell (MASC), which has the capacity to be induced to differentiate to form at least one differentiated cell type of mesodermal, ectodermal or endodermal origin, is new. Independent claims are also included for: (1) creating (M1) a normal non-human animal; (2) compositions comprising: (a) a population of MASC and a medium, where the culture medium expands the MASC; or (b) a population of fully or partially purified MASC progeny; (3) isolating (M2) and propagating the MASC; (4) an expanded MASC population obtained by (M2); (5) differentiating (M3) MASC ex vivo or in vivo; (6) differentiated cells obtained by (M3); (7) a therapeutic composition comprising MASC and a pharmaceutical carrier, where the MASC are present in to produce bone marrow, blood, spleen, liver, lung, intestinal tract, eye, brain, immune system, bone, connective tissue, muscle, heart, blood vessels, pancreas, central nervous system, kidney, bladder, skin, epithelial appendages, breast-mammary gland, fat or mucosal surface (e.g. oral, esophageal, vaginal or anal) tissues; (8) restoring (M4) organ tissue or cellular function to a patient; (9) inhibiting (M5) the rejection of a heterologous MASC transplanted into a patient; (10) generating (M6) blood or individual blood components ex vivo; (11) drug discovery; (12) identifying (M7) the components of a differentiation pathway; (13) comparing (M8) differentiation in vitro with differentiation in vivo by comparing the results obtained in (M7); (14) identifying (M9) the molecular components of disease or injury; (15) generating (M10) products (which have therapeutic, diagnostic or research utility) in vitro; (16) inducing (M11) in a mammal, tolerance to an antigen administered to the mammal; (17) removing (M12) toxins from the blood of a patient; (18) delivering (M13) therapeutic products to a patient; and (19) testing (M14) the toxicity of a drug. ACTIVITY : Cytostatic; Cardiant; Cardiovascular; Hepatotropic; Hemostatic; Antidiabetic; Virucide; Anti-inflammatory; Vasotropic; Neuroprotective; Antianemic; Cerebroprotective; Immunosuppressant; Antibacterial. No biological data given. MECHANISM OF ACTION : Cell Replacement Therapy.
-
3.发明公开MULTIPOTENT ADULT STEM CELLS, SOURCES THEREOF, METHODS OF OBTAINING AND MAINTAINING SAME, METHODS OF DIFFERENTIATION THEREOF, METHODS OF USE THEREOF AND CELLS DERIVED THEREOF 审中-公开多成体干细胞，基本物质。确保恢复过程中保护和分化及其方法，使用方法用途，您始发细胞
公开(公告)号：EP1367899A4
公开(公告)日：2004-07-28
申请号：EP02718998
申请日：2002-02-14
IPC分类号： A01K67/027 , A01N63/00 , A61D19/04 , A61K35/12 , A61K35/14 , A61K35/28 , A61K35/30 , A61K35/32 , A61K35/39 , A61K35/407 , A61K35/44 , A61K39/00 , A61K45/00 , A61K47/46 , A61K48/00 , A61L27/00 , A61L31/00 , A61P1/00 , A61P1/16 , A61P1/18 , A61P3/00 , A61P3/10 , A61P7/00 , A61P7/04 , A61P7/06 , A61P7/08 , A61P9/00 , A61P9/10 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P19/04 , A61P19/08 , A61P21/00 , A61P25/00 , A61P25/02 , A61P27/02 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P35/00 , A61P37/00 , A61P37/06 , A61P39/02 , A61P41/00 , A61P43/00 , C07K1/00 , C07K14/00 , C12N20060101 , C12N5/00 , C12N5/02 , C12N5/071 , C12N5/074 , C12N5/079 , C12N5/0793 , C12N15/00 , C12N15/85 , C12N15/873 , C12Q1/02 , C12Q1/68 , G01F19/00 , G01N33/48 , G01N33/50
CPC分类号： A61K39/001 , A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/106 , A61K35/12 , A61K48/00 , C12N5/0607 , C12N5/0619 , C12N5/0622 , C12N5/067 , C12N15/873 , C12N2501/11 , C12N2501/113 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/135 , C12N2501/235 , C12N2501/237 , C12N2502/08 , C12N2502/30 , C12N2503/00 , C12N2506/03 , C12N2517/02
摘要： An isolated multipotent adult stem cell (MASC), which has the capacity to be induced to differentiate to form at least one differentiated cell type of mesodermal, ectodermal or endodermal origin, is new. Independent claims are also included for: (1) creating (M1) a normal non-human animal; (2) compositions comprising: (a) a population of MASC and a medium, where the culture medium expands the MASC; or (b) a population of fully or partially purified MASC progeny; (3) isolating (M2) and propagating the MASC; (4) an expanded MASC population obtained by (M2); (5) differentiating (M3) MASC ex vivo or in vivo; (6) differentiated cells obtained by (M3); (7) a therapeutic composition comprising MASC and a pharmaceutical carrier, where the MASC are present in to produce bone marrow, blood, spleen, liver, lung, intestinal tract, eye, brain, immune system, bone, connective tissue, muscle, heart, blood vessels, pancreas, central nervous system, kidney, bladder, skin, epithelial appendages, breast-mammary gland, fat or mucosal surface (e.g. oral, esophageal, vaginal or anal) tissues; (8) restoring (M4) organ tissue or cellular function to a patient; (9) inhibiting (M5) the rejection of a heterologous MASC transplanted into a patient; (10) generating (M6) blood or individual blood components ex vivo; (11) drug discovery; (12) identifying (M7) the components of a differentiation pathway; (13) comparing (M8) differentiation in vitro with differentiation in vivo by comparing the results obtained in (M7); (14) identifying (M9) the molecular components of disease or injury; (15) generating (M10) products (which have therapeutic, diagnostic or research utility) in vitro; (16) inducing (M11) in a mammal, tolerance to an antigen administered to the mammal; (17) removing (M12) toxins from the blood of a patient; (18) delivering (M13) therapeutic products to a patient; and (19) testing (M14) the toxicity of a drug. ACTIVITY : Cytostatic; Cardiant; Cardiovascular; Hepatotropic; Hemostatic; Antidiabetic; Virucide; Anti-inflammatory; Vasotropic; Neuroprotective; Antianemic; Cerebroprotective; Immunosuppressant; Antibacterial. No biological data given. MECHANISM OF ACTION : Cell Replacement Therapy.
-
4.发明公开Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof 有权多波坦特成体干细胞，原料为他们获取和保留，分化技术及其使用方法，以及细胞程序从中派生
公开(公告)号：EP1491093A2
公开(公告)日：2004-12-29
申请号：EP04023157.3
申请日：2002-02-14
IPC分类号： A01N63/00
CPC分类号： A61K39/001 , A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/106 , A61K35/12 , A61K48/00 , C12N5/0607 , C12N5/0619 , C12N5/0622 , C12N5/067 , C12N15/873 , C12N2501/11 , C12N2501/113 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/135 , C12N2501/235 , C12N2501/237 , C12N2502/08 , C12N2502/30 , C12N2503/00 , C12N2506/03 , C12N2517/02
摘要： The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.
摘要翻译： 一种分离的多成体干细胞（MASC），其具有能力，被诱导分化以形成中胚层，外胚层或内胚层来源的至少一种分化的细胞类型，是新的。 独立权利要求，因此包括用于：（1）创建（M1）正常非人动物; （2）组合物包括：（A）MASC和介质，其中，所述培养基的扩展MASC群; 或（b）完全或部分纯化的MASC后代群体; （3）分离（M2）和传播MASC; （4）由（M2）得到的发泡MASC群; （5）区分（M3）MASC离体或在体内; （6）由（M3）中获得的分化细胞; （7）一种治疗组合物，包含MASC和药用载体，其中该MASC存在于产生骨髓，血液，脾，肝，肺，肠道，眼睛，大脑，免疫系统，骨，结缔组织，肌肉，心脏 ，血管，胰腺，中枢神经系统，肾脏，膀胱，皮肤，上皮附属物，乳房乳腺gland-，脂肪或粘膜表面（如口腔，食道，阴道或肛门的）组织; （8）恢复（M4）器官组织或细胞的功能的患者; （9）抑制（M5）的排斥移植到患者体内的异源MASC的; （10）产生（M6）的血液或单个血液成分的离体; （11）药物发现; （12）确定（M7）一个分化途径的组分; （13）通过比较在（M7）中获得的结果相比较的体外（M8）的分化与体内分化; （14）确定（M9）的疾病或损伤的分子组分; （15）生成（M10）的产品（其具有治疗，诊断或研究效用）体外; （16）在哺乳动物中诱导（M11），对上给予哺乳动物抗原; （17）去除从患者的血液中（M12）毒素; （18）传送（M13）的治疗产品的患者; 和（19）测试（M14）的药物的毒性。 活动：抑制细胞; Cardiant; 心血管; 嗜肝; 止血; 降糖; 杀病毒; 抗炎; Vasotropic; 神经保护; 抗贫血药; 脑保护; 免疫抑制剂; 抗菌。 无生物数据给出。 作用机制：细胞替代治疗。
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
